Wednesday, October 17, 2007

Genzyme And Bayer Schering To Present New Data On Alemtuzumab In Multiple Sclerosis At ECTRIMS
Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) underway in Prague.
15 Oct 2007

Biogen Idec And Elan Provide Update On Utilization And Safety Of TYSABRI® In Patients With Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced new data on the global utilization and safety of TYSABRI® (natalizumab), citing that as of the end of September 2007 approximately 17,000 patients are on commercial and clinical therapy worldwide, and that the safety data to date continue to support a favorable benefit-risk profile for TYSABRI.
15 Oct 2007

Multiple Sclerosis Disability May Be Accelerated By Cigarette Smoking
Persons with multiple sclerosis who smoke risk increasing the amount of brain tissue shrinkage, a consequence of MS, and the subsequent severity of their disease, new research conducted at the Buffalo Neuroimaging Analysis Center (BNAC) at the University at Buffalo has shown.
15 Oct 2007

How Genetic Make-Up Affects Multiple Sclerosis
Magnetic resonance images (MRI) of a large group of patients with multiple sclerosis has provided the first evidence that those with a history of MS in their families show more severe brain damage than patients who have no close relatives with the disease.
15 Oct 2007

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home